Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Net Margin: 2010-2025

Historic Net Margin for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to 6.29%.

  • Arrowhead Pharmaceuticals' Net Margin fell 117719.00% to 6.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.62%, marking a year-over-year decrease of 259812.00%. This contributed to the annual value of 3.63% for FY2025, which is 1717324.00% up from last year.
  • Arrowhead Pharmaceuticals' Net Margin amounted to 6.29% in Q3 2025, which was up 100.98% from -643.40% recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' Net Margin's 5-year high stood at 3,415.33% during Q2 2024, with a 5-year trough of -7,008.72% in Q4 2024.
  • Its 3-year average for Net Margin is -577.57%, with a median of 6.29% in 2025.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Net Margin surged by 407,331bps in 2024, and later slumped by 405,873bps in 2025.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Net Margin stood at -229.13% in 2021, then skyrocketed by 16,229bps to -66.85% in 2022, then crashed by 374,549bps to -3,812.33% in 2023, then crashed by 319,639bps to -7,008.72% in 2024, then plummeted by 117,719bps to 6.29% in 2025.
  • Its last three reported values are 6.29% in Q3 2025, -643.40% for Q2 2025, and 67.77% during Q1 2025.